Gillessen A, Schmidt HH. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37:1279–301. https://doi.org/10.1007/s12325-020-01251-y

Article  PubMed  PubMed Central  Google Scholar 

Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15:465–89. https://doi.org/10.2165/00063030-200115070-00005

Article  CAS  PubMed  Google Scholar 

Sahibzada MUK, Zahoor M, Sadiq A, Ur Rehman F, Al-Mohaimeed AM, Shahid M, et al. Bioavailability and hepatoprotection enhancement of berberine and its nanoparticles prepared by liquid antisolvent method. Saudi J Biol Sci. 2021;28:327–32. https://doi.org/10.1016/j.sjbs.2020.10.006

Article  CAS  PubMed  Google Scholar 

Garcia-Maceira P, Mateo J. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene. 2009;28:313–24. https://doi.org/10.1038/onc.2008.398

Article  CAS  PubMed  Google Scholar 

Ting H, Deep G, Agarwal R. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer. AAPS J. 2013;15:707–16. https://doi.org/10.1208/s12248-013-9486-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polachi N, Bai G, Li T, Chu Y, Wang X, Li S, et al. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - a comprehensive review. Eur J Med Chem. 2016;123:577–95. https://doi.org/10.1016/j.ejmech.2016.07.070

Article  CAS  PubMed  Google Scholar 

Aziz MA, Sarwar MS, Akter T, Uddin MS, Xun S, Zhu Y, et al. Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. Life Sci. 2021;268:118999. https://doi.org/10.1016/j.lfs.2020.118999

Article  CAS  PubMed  Google Scholar 

Roca E, Colloca G, Lombardo F, Bellieni A, Cucinella A, Madonia G, et al. The importance of integrated therapies on cancer: silibinin, an old and new molecule. Oncotarget. 2024;15:345–53. https://doi.org/10.18632/oncotarget.28587

Article  PubMed  PubMed Central  Google Scholar 

Bosch-Barrera J, Menendez JA. Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 2015;41:540–6. https://doi.org/10.1016/j.ctrv.2015.04.008

Article  CAS  PubMed  Google Scholar 

Si L, Fu J, Liu W, Hayashi T, Nie Y, Mizuno K, et al. Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of mitochondrial fusion. Mol Cell Biochem. 2020;463:189–201. https://doi.org/10.1007/s11010-019-03640-6

Article  CAS  PubMed  Google Scholar 

Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants. 2015;4:204–47. https://doi.org/10.3390/antiox4010204

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu XX, Ding YH, Wu Y, Qian LY, Zou H, He Q. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol. 2016;9:1323–30. https://doi.org/10.1080/17512433.2016.1208563

Article  CAS  PubMed  Google Scholar 

Romanidou O, Imbimbo M, Mountzios G, Abidin A, Morgillo F, Califano R. Therapies in the pipeline for small-cell lung cancer. Br Med Bull. 2016;119:37–48. https://doi.org/10.1093/bmb/ldw022

Article  CAS  PubMed  Google Scholar 

van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55. https://doi.org/10.1016/S0140-6736(11)60165-7

Article  PubMed  Google Scholar 

Sharma G, Singh RP, Chan DC, Agarwal R. Silibinin induces growth inhibition and apoptotic cell death in human lung carcinoma cells. Anticancer Res. 2003;23:2649–55.

CAS  PubMed  Google Scholar 

Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics. 2012;7:1161–72. https://doi.org/10.4161/epi.22070

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray PP, Islam MA, Islam MS, Han A, Geng P, Aziz MA, et al. A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment. Front Pharmacol. 2024;15:1349745. https://doi.org/10.3389/fphar.2024.1349745

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liakopoulou C, Kazazis C, Vallianou NG. Silimarin and cancer. Anticancer Agents Med Chem. 2018;18:1970–74. https://doi.org/10.2174/1871520618666180905154949

Article  CAS  PubMed  Google Scholar 

Delmas D, Xiao J, Vejux A, Aires V. Silymarin and cancer: a dual strategy in both chemoprevention and chemosensitivity. Molecules. 2020;25:2009. https://doi.org/10.3390/molecules25092009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bosch-Barrera J, Sais E, Canete N, Marruecos J, Cuyas E, Izquierdo A, et al. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget. 2016;7:32006–14. https://doi.org/10.18632/oncotarget.7900

Article  PubMed  PubMed Central  Google Scholar 

Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, et al. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med. 2018;24:1024–35. https://doi.org/10.1038/s41591-018-0044-4

Article  CAS  PubMed  Google Scholar 

Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res. 2004;10:8641–47. https://doi.org/10.1158/1078-0432.CCR-04-1435

Article  CAS  PubMed  Google Scholar 

Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther. 2008;7:1817–26. https://doi.org/10.1158/1535-7163.MCT-08-0256

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res. 2009;2:74–83. https://doi.org/10.1158/1940-6207.CAPR-08-0095

Article  CAS  Google Scholar 

Ramasamy K, Dwyer-Nield LD, Serkova NJ, Hasebroock KM, Tyagi A, Raina K, et al. Silibinin prevents lung tumorigenesis in wild-type but not in iNOS-/- mice: potential of real-time micro-CT in lung cancer chemoprevention studies. Clin Cancer Res. 2011;17:753–61. https://doi.org/10.1158/1078-0432.CCR-10-2290

Article  CAS  PubMed  Google Scholar 

Samant GV, Sylvester PW, Verma AK. Silibinin suppresses UVB-induced skin cancer by reducing cyclooxygenase-2 expression and inhibiting prostaglandin E2 production. Mol Carcinog. 2006;45:320–31. https://doi.org/10.1002/mc.20194

Article  CAS  Google Scholar 

Mandegary A, Eftekhari P, Pishva A, Zare R, Sharififar F. The effect of silymarin on cisplatin nephrotoxicity in patients with cancer undergoing chemotherapy: a randomized, double-blind, placebo-controlled clinical trial. Phytother Res. 2014;28:633–40. https://doi.org/10.1002/ptr.5030

Article  CAS  Google Scholar 

Kim SH, Oh DS, Jeong D, Lee YS, Kim SH. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in head and neck squamous c